Ownership Submission

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:

3235-0104

Estimated average burden hours per response...

0.5

(Print or Type Responses)

1. Name and Address of Reporting Person ^*

IPSA (INNOVEN PARTENAIRES S.A.)

2. Date of Event Requiring Statement (Month/Day/Year)
02/12/2015

3. Issuer Name and Ticker or Trading Symbol
EYEGATE PHARMACEUTICALS INC [EYEG]

(Last)

(First)

(Middle)

10 RUE DE LA PAIX

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

_____ Director	__X__ 10% Owner
_____ Officer (give title below)	_____ Other (specify below)

5. If Amendment, Date Original Filed(Month/Day/Year)

(Street)

PARIS, I0 75002

6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

(City)

(State)

(Zip)

Table I - Non-Derivative Securities Beneficially Owned

1.Title of Security
(Instr. 4)

2. Amount of Securities Beneficially Owned
(Instr. 4)

3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)

4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.			SEC 1473 (7-02)
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security		6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series B Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	524,998	$ ⁽²⁾	I	See Footnote ⁽³⁾ ⁽⁴⁾
Series C Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	169,306	$ ⁽⁵⁾	I	See Footnote ⁽⁴⁾ ⁽⁶⁾
Series D Preferred Stock	⁽¹⁾	⁽¹⁾	Common Stock	261,314	$ ⁽⁷⁾	I	See Footnote ⁽⁴⁾ ⁽⁸⁾
Common Stock Warrants (right to buy)	01/01/2015	06/06/2019	Common Stock	89,172	$ ⁽⁹⁾	I	See Footnote ⁽⁴⁾ ⁽¹⁰⁾

Reporting Owners

Reporting Owner Name / Address	Relationships
Reporting Owner Name / Address	Director	10% Owner	Officer	Other
IPSA (INNOVEN PARTENAIRES S.A.) 10 RUE DE LA PAIX PARIS, I0 75002		X

Signatures

/s/ Authorized Signatory*		02/12/2015
^**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 5(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Innoven 2002 FCPI No6, Innoven 2003 FCPI No7, FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Europe 3, FCPI Innoven Capital, FCPI Innoven Capital 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5, FCPI Poste Innovation 6, FCPI Poste Innovation 9 and FCPI La Banque Postale Innovation 1 (collectively, the "Funds") hold shares in Issuer's wholly owned subsidiary, EyeGate Pharma S.A.S. ("Subsidiary Stock"). The Subsidiary Stock is automatically exchanged into Issuer's Preferred Stock immediately prior to the closing of the Issuer's initial public offering, which will automatically convert into Common Stock immediately prior to the closing of Issuer's initial public offering. There is no expiration date for any series of Preferred Stock.
(2)	All outstanding shares of the Issuer's Series B Preferred Stock will automatically convert on a 10.94-for-one basis into Common Stock as shown in column 3 immediately upon the closing of the Issuer's initial public offering, for no additional consideration.
(3)	Represents 26,994, 71,111, 16,416, 711,099, 428,115, 599,019, 817,685, 2,203,862, 885,941, and 4,288 shares held by Innoven 2002 FCPI No6, Innoven 2003 FCPI No7, FCPI Innoven Europe, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5, FCPI Poste Innovation 6, FCPI Poste Innovation 9, and FCPI La Banque Postale Innovation 1, respectively.
(4)	Innoven Partenaires S.A. ("IPSA") is the manager of each of the Funds. Voting and investment power over the shares held by each of the Funds may be deemed to be shared with IPSA. Each of Jean-Michel Paulhac ("Paulhac") and Thomas Balland ("Balland ") are directors of IPSA. Each of Paulhac and Balland disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein.
(5)	All outstanding shares of the Issuer's Series C Preferred Stock will automatically convert on a 9.60-for-one basis into Common Stock as shown in column 3 immediately upon the closing of the Issuer's initial public offering, for no additional consideration.
(6)	Represents 324,574, 31,532, 217,235, 89,946, 139,349, 269,507 and 786,837 shares held by FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, FCPI Poste Innovation 5 and FCPI La Banque Postale Innovation 1, respectively.
(7)	All outstanding shares of the Issuer's Series D Preferred Stock will automatically convert on a 10.96-for-one basis into Common Stock as shown in column 3 immediately upon the closing of the Issuer's initial public offering, for no additional consideration.
(8)	Represents 1,163, 527,940, 429,985, 361,720, 84,327, 920,096, 219,702, 219,862, 216 and 104,236 shares held by FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Europe 3, FCPI Innoven Capital, FCPI Innoven Capital 2, FCPI Poste Innovation, FCPI Poste Innovation 2, FCPI Poste Innovation 3, and FCPI La Banque Postale Innovation 1, respectively.
(9)	The per-share exercise price will be equal to the price per share at which shares of Common Stock are sold to the public pursuant to the Company's initial public offering.
(10)	Represents 1,381, 3,246, 8,527, 4,872, 45,389, 19,589 and 6,168 warrants held by Innoven 2003 FCPI No7, FCPI Innoven Europe, FCPI Innoven Europe 2, FCPI Innoven Capital 2, FCPI Poste Innovation 5, FCPI Poste Innovation 6 and FCPI La Banque Postale Innovation 1, respectively.
Remarks: *Signed under power of attorney on behalf of Reporting Person

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.